RxDoctor Payments Data

Travis Bailey, DO

Pain Medicine · Valdosta, GANPI 1164711313

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,761 of the $7,346 with a category attached, or 78.4%. 27 manufacturers reported payments, led by Nevro Corp. at 38.9% of the total. Reporting peaked in 2022 at $2,948 and has fallen 87.0% since, to $382 in 2025.

$7,346in general payments, 2019–2025

Across 229 payments — averaging $32.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$3K
  • Spinal Simplicity, LLC$2K
  • Vertos Medical, Inc.$552
  • Painteq LLC$437
  • Boston Scientific$357
  • Abbott$247
  • plus $925 from 21 others

What the payments were for

  • Travel & lodging$1,58622%
  • Food & beverage$5,76178%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,346 in reported general payments places this provider in the 80th percentile of 203 pain medicine providers in Georgia.

See all pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$293,953
Medicare patients
479
Services billed
4,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,589$59,692
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,375$39,083
Xtampza ErOxycodone Myristate20$23,525
NucyntaTapentadol Hcl17$18,669
Pregabalin636$10,797
Oxycodone Hcl327$10,619
Buprenorphine22$7,279
MovantikNaloxegol Oxalate15$6,483
Fentanyl43$5,520
Gabapentin423$5,022
Diclofenac Sodium51$3,963
Morphine Sulfate ErMorphine Sulfate124$3,760
Celecoxib206$3,319
Buprenorphine Hcl85$2,813
Duloxetine Hcl280$2,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta$30$42,19437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 203 pain medicine providers in Georgia.

Other pain medicine in Valdosta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →